Home Conditions A–Z Giant cell arteritis and arteritic AION

Giant cell arteritis and arteritic AION

An emergency that can affect both eyes

Reviewed by Dr. James Deom, OD, MPH, FAAO, FSLS, Chief of Eye Care Services, Hazleton Eye Specialists Last reviewed: November 12, 2026 Audience: All (patient and clinician sections)

Same-day care

Sudden vision loss in one eye needs same-day care.

Call an eye doctor or go to the emergency department.

Call the office 570-453-2020 Find an eye doctor 5 offices Schedule an exam Pick your office

Over 50 with sudden vision loss, double vision, or brief blackouts of vision, plus a new headache, jaw pain when chewing, scalp tenderness, fever, or unexplained weight loss? Go to the emergency department now. Giant cell arteritis can cause permanent blindness, sometimes in both eyes, and treatment should not wait.

For patients and families

What it is

Giant cell arteritis (GCA), also called temporal arteritis, is inflammation of medium and large arteries, including arteries in the head that supply the eyes.¹ ² It almost always affects people over 50, and it is more common in women.¹ When the inflamed arteries feeding the optic nerve close off, the result is arteritic anterior ischemic optic neuropathy (arteritic AION), a sudden loss of vision that is usually permanent.² ³

Warning signs

A new headache, often at the temples
Scalp tenderness (for example, when brushing your hair)
Jaw pain or tiredness when chewing
Fever, tiredness, night sweats, or weight loss without trying
Aching and stiffness in the shoulders or hips (polymyalgia rheumatica)
Brief episodes of blurred or lost vision, or double vision, which can come before permanent loss³

Why it is an emergency

Without treatment, GCA can take vision in the second eye, sometimes within days.³ Steroid medicine started quickly is the main way to protect remaining vision.¹ That is why we ask anyone over 50 with sudden vision changes about these symptoms.

What to expect

Blood tests (ESR and CRP) are usually done right away. Steroids are often started before other tests are finished. A small sample of the temple artery (biopsy) or an ultrasound of the arteries may be used to confirm the diagnosis.¹ ⁴ Treatment usually continues for many months and is managed with a rheumatologist or your primary doctor.

GLP-1 medicines and GCA

GCA is not known to be caused by GLP-1 medicines. It matters here because sudden vision loss in an older adult taking a GLP-1 medicine might be assumed to be NAION. GCA has to be ruled out first, because it is treatable and can threaten both eyes. If you take a GLP-1 medicine, the warning signs above still mean the emergency department.

Dr. Deom’s recommendation (clinical opinion / practice recommendation)

Dr. James Deom recommends that everyone starting or taking a GLP-1 medication have a comprehensive dilated eye exam with OCT, OCT angiography (OCTA), and retinal photography (fundus photos with autofluorescence) as a baseline and for follow-up, and seek same-day care for sudden vision loss.

This is his clinical opinion, not a formal rule from every professional group. AAO and NANOS do not recommend an eye exam only to predict NAION, and no test can reliably predict or prevent it. Dr. Deom recommends the baseline so there is a record to compare against if anything changes, and so other eye problems can be found early.

Dr. James Deom’s personal clinical thought

This is his opinion, not established evidence. It is not a finding from the studies or a position of the FDA, EMA, AAO, NANOS, or AOA.

As people lose weight and get healthier on GLP-1 medicines, their blood pressure and cholesterol medicines are often not reviewed or adjusted. Blood pressure treatment that is no longer matched to a person’s needs may lead to low blood pressure (hypotension). Low blood pressure can be more pronounced at night and could reduce blood flow to the optic nerve during sleep. That possibility would fit the typical way NAION presents: vision loss noticed on waking.

Dr. Deom recommends that people taking a GLP-1 medicine also work on exercise and diet, and keep regular visits with their usual doctors — even if that doctor did not prescribe the GLP-1 — so the rest of their care, including blood pressure, is maintained. Do not start, stop, or change a blood pressure or cholesterol medicine on your own; talk with the clinician who prescribes it.

For clinicians

When to suspect GCA

Any patient over 50 with acute vision loss, transient monocular vision loss, diplopia, or a new headache
Constitutional symptoms, jaw claudication, scalp tenderness, PMR symptoms
Ocular findings: pallid (“chalky-white”) disc edema, cilioretinal artery occlusion, central retinal artery occlusion, cotton-wool spots, or delayed choroidal filling on angiography.³ A normal-appearing disc does not exclude posterior ischemic optic neuropathy from GCA (see PION).
“Occult” GCA without systemic symptoms has been described, so the absence of headache does not exclude it.⁵

Work-up and treatment (summary of guidance)

Same day: ESR, CRP, and CBC with platelets. Normal inflammatory markers lower but do not eliminate the probability.
Start high-dose glucocorticoids promptly when GCA is suspected, without waiting for biopsy or imaging. The 2021 ACR/Vasculitis Foundation guideline addresses oral versus IV pulse dosing for patients with vision loss or threatened vision.¹
Confirm the diagnosis with temporal artery biopsy (ACR favors a long segment) or vascular ultrasound where local expertise exists, as in the 2023 EULAR imaging recommendations.¹ ⁴ Biopsy yield falls the longer steroids have been given, so arrange it soon after treatment starts.⁶
Steroid-sparing therapy: in the GiACTA trial, tocilizumab with a 26-week prednisone taper improved sustained remission compared with a steroid taper alone.⁷ The ACR guideline addresses its use.¹
Coordinate with rheumatology for long-term management.

Use the GCA checklist for eye doctors for a step-by-step version.

GLP-1 RA context

In a patient over 50 on a GLP-1 RA who presents with acute optic neuropathy, exclude GCA before attributing the event to NAION, document the work-up, and notify the prescriber.

Dr. Deom’s recommendation (clinical opinion / practice recommendation)

This is his clinical opinion and practice recommendation, not a society mandate. AAO and NANOS do not recommend routine examination solely to predict NAION, and no exam or imaging test reliably predicts or prevents an acute event. The baseline is intended to document disc anatomy and retinal status for later comparison and to detect other eye disease. See the study comparison for where professional positions agree and differ.

Dr. James Deom’s personal clinical thought

This is his opinion, not established evidence. It is not a finding from the studies or a position of the FDA, EMA, AAO, NANOS, or AOA.

As patients lose weight and their overall health improves on GLP-1 medicines, blood pressure and cholesterol medicines are often not re-addressed. Over-treatment of blood pressure may lead to hypotension, which can worsen at night and could cause nighttime hypoperfusion of the optic nerve. That sequence would fit the typical presentation of NAION (vision loss noticed on waking).

He recommends that people on GLP-1 medicines also improve exercise and diet, and keep regular visits with their usual doctors, even if that clinician did not prescribe the GLP-1, so the rest of their care, including blood pressure, is maintained.

For prescribers: consider reviewing antihypertensive dosing and timing (including bedtime dosing) as weight drops. Coordinate changes with the patient’s usual clinician when someone else wrote the GLP-1 prescription.

How to reach us

Same-day evaluation: providers can call the office at 570-453-2020 (fax 570-453-1020), or refer a patient or ask a question by email. Patients can schedule an exam online.

For privacy, please don’t include patient names or other identifying details in email. Our team will call to schedule and gather details securely.

General contact and referrals: Hazleton Eye Specialists, phone 570-453-2020, fax 570-453-1020. See Referral information for what to send.

References

Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. https://pubmed.ncbi.nlm.nih.gov/34235884/
Biousse V, Newman NJ. Ischemic Optic Neuropathies. N Engl J Med. 2015;372(25):2428-2436. https://pubmed.ncbi.nlm.nih.gov/26083207/
Hayreh SS, et al. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509-520. https://pubmed.ncbi.nlm.nih.gov/9559737/
Dejaco C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83(6):741-751. https://pubmed.ncbi.nlm.nih.gov/37550004/
Hayreh SS, et al. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125(4):521-526. https://pubmed.ncbi.nlm.nih.gov/9559738/
Papadakos SP, et al. The Effect of Corticosteroids on Temporal Artery Biopsy Positivity in Giant Cell Arteritis: Timing is Everything. J Clin Rheumatol. 2023;29(4):173-176. https://pubmed.ncbi.nlm.nih.gov/36728371/
Stone JH, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317-328. https://pubmed.ncbi.nlm.nih.gov/28745999/
American Academy of Ophthalmology. Giant Cell Arteritis (patient information). https://www.aao.org/eye-health/diseases/giant-cell-arteritis · EyeWiki: Giant Cell Arteritis. https://eyewiki.org/Giant_Cell_Arteritis

Medical disclaimer. This page is for general education. The patient section is not medical advice, and the clinician section is not a clinical practice guideline; neither replaces an examination, clinical judgment, or specialty consultation. If you have sudden vision loss, seek same-day care from an eye doctor or an emergency department. Information is current as of the “last reviewed” date.